https://www.biospace.com/press-releases/arvinas-to-present-at-jefferies-global-healthcare-conference-2025
Arvinas to Present at Jefferies Global Healthcare Conference 2025 - BioSpace
global healthcarearvinaspresentjefferiesconference
https://www.arvinas.com/
Targeted Protein Degradation Therapeutics | Arvinas
Apr 28, 2026 - Arvinas is a clinical-stage biotechnology company leading the way in targeted protein degradation therapeutics.
targeted protein degradationtherapeuticsarvinas
https://www.home.saxo/de-ch/markets/stocks/arvn-xnas
Arvinas Inc. aktie | Saxo Bank Schweiz
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases...
saxo bankarvinasincaktieschweiz
https://www.home.saxo/pl-pl/markets/stocks/arvn-xnas
Arvinas Inc. akcja | Saxo Bank
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases...
arvinasincakcjasaxobank
https://www.globenewswire.com/de/news-release/2025/06/24/3103911/0/en/Bragar-Eagel-Squire-P-C-Is-Investigating-Arvinas-Semler-and-Abacus-and-Encourages-Investors-to-Contact-the-Firm.html
Bragar Eagel & Squire, P.C. Is Investigating Arvinas,
p cis investigatingbragareagelsquire
https://www.fiercebiotech.com/biotech/bayer-inks-arvinas-deal-to-develop-protein-degraders
Bayer inks Arvinas deal to develop protein degraders | Fierce Biotech
to developprotein degradersbayerinksarvinas
https://www.nasdaq.com/market-activity/stocks/arvn/financials
Arvinas, Inc. Common Stock (ARVN) Financials | Nasdaq
Find the latest Arvinas, Inc. Common Stock (ARVN) annual income statements, balance sheets, financial statements, ratios, and cash flow data at Nasdaq.com.
common stockarvinasincarvnfinancials
https://www.macrotrends.net/stocks/charts/ARVN/arvinas/roa
Arvinas ROA 2017-2025 | ARVN | MacroTrends
Current and historical return on assets (ROA) values for Arvinas (ARVN) over the last 10 years. Return on assets can be defined as an indicator of how...
arvinasroa20172025arvn
https://www.macrotrends.net/stocks/charts/ARVN/arvinas/balance-sheet
Arvinas Balance Sheet 2016-2026 | ARVN | MacroTrends
Ten years of annual and quarterly balance sheets for Arvinas (ARVN). The balance sheet is a financial report that shows the assets of a business (i.e. what it...
balance sheetarvinas20162026arvn
https://www.benzinga.com/general/biotech/25/03/44255339/arvinas-pfizer-breast-cancer-drug-fails-to-show-progression-free-survival-benefit-in-trial
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial -...
Mar 11, 2025 - Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.
https://www.macrotrends.net/stocks/charts/ARVN/arvinas/price-sales
Arvinas Price to Sales Ratio 2017-2026 | ARVN | MacroTrends
price to sales ratioarvinas20172026arvn
https://www.macrotrends.net/stocks/charts/ARVN/arvinas/debt-equity-ratio
Arvinas Debt to Equity Ratio 2017-2026 | ARVN | MacroTrends
Current and historical debt to equity ratio values for Arvinas (ARVN) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's...
debt to equity ratioarvinas20172026arvn
https://www.benzinga.com/25/03/44247959/us-stocks-mixed-kohls-shares-plunge-after-q4-results
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results - Arvinas (NASDAQ:ARVN) - Benzinga
https://www.benzinga.com/24/12/42421011/arvinas-pfizer-partner-cancer-cancer-drug-shows-63-clinical-benefit-rate-in-combo-therapy-trial-in-breast-cancer-
Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients -...
Dec 10, 2024 - Arvinas and Pfizer share Phase 1b TACTIVE-U trial results showing 62.5% clinical benefit rate and tolerable safety for advanced breast cancer therapy.
https://www.finanznachrichten.de/nachrichten-2025-03/64790111-pre-market-movers-2seventy-bio-sonoma-pharmaceuticals-tenon-medical-arvinas-net-power-inc-020.htm
Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc.
LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc....
https://www.insidermonkey.com/blog/should-i-avoid-arvinas-inc-arvn-1014973/
Should I Avoid Arvinas, Inc. (ARVN)? - Insider Monkey
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
should iavoidarvinasincarvn
https://finviz.com/news/336272/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurological-disorders
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026...
Stock screener for investors and traders, financial visualizations.
https://www.benzinga.com/insights/analyst-ratings/24/02/36886451/forecasting-the-future-6-analyst-projections-for-arvinas
Forecasting The Future: 6 Analyst Projections For Arvinas - Arvinas (NASDAQ:ARVN) - Benzinga
forecasting the future6analyst
https://investingnews.com/news/market-news/arvinas-and-pfizer-announce-updated-phase-1-dose-escalation-data-for-arv-471-to-be-presented-in-spotlight-poster-session-at-2021-san-antonio-breast-cancer-symposium/
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in...
Feb 23, 2022 - Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose escalation trial of...
https://theorg.com/org/arvinas?person=jingjing-bu
Arvinas | The Org
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases...
arvinas
https://www.fiercebiotech.com/research/asco-arvinas-unveils-first-human-data-for-novel-protein-degrader-prostate-cancer
ASCO: Arvinas unveils first-in-human data for novel protein degrader in prostate cancer | Fierce...
May 13, 2020 - Many widely used oncology therapies work by inhibiting cancer-related proteins. But what if we simply destroyed those proteins rather than trying to block...